News

Is Teva knocking on Mylan's door? With inversion deal at risk, maybe

Teva and Mylan merge? Rumors are certainly swirling--and not for the first time, either. But while a potential deal might make financial sense, at least one analyst doesn't see it happening.

AstraZeneca crows about Brilinta edge in new ACS treatment guidelines

Ever since Pascal Soriot took the reins at AstraZeneca, he's been talking up Brilinta as a diamond in the rough. With some work, the clot-fighting drug really could become a blockbuster, the CEO figures. No, really.

Endo accused of $112M payoff in Opana pay-for-delay suit

Endo Health Solutions tried hard to ward off generic competitors for its big-selling pain med Opana ER. For instance, it petitioned the FDA to block competitors on safety grounds. According to a new lawsuit, Endo also paid off generics maker--and potential rival--Impax Laboratories.

Peg cancer drug prices to effectiveness, '60 Minutes' interviewee suggests

On "60 Minutes," Dr. Peter Bach and Leonard Saltz deliver some sound bites that might get the general public talking--and politicians, too.

Top execs bicker over Sanofi's plan to unload $8B portfolio of old drugs

Back in April, Sanofi CEO Chris Viehbacher said he planned to sell off some of the company's mature products to make room for higher-value "bolt-on" acquisitions. Rumors about potential buyers immediately started flying. Analysts estimated the drugs could fetch $8 billion or more.

Takeda back in court facing bladder cancer claims against Actos

Lawyers in another Actos failure-to-warn trial claimed the company put profits ahead of patient safety, by keeping mum on study data that flagged links between the diabetes drug and cancer.

Catalyst Pharma to join parade of huge price hikes on old, cheap drugs

Yet another drugmaker is taking a cheap drug and turning it into an FDA-approved brand--and adding an enormous premium along the way. Once again, the cost increase promises to be huge, The Street reports: Analysts figure on a list price of $60,000 to $80,000 per year.

Add Arbor Pharma to your shopping list: It's on the block for $1B-plus

It's a good time to be a specialty drugmaker--especially one looking to sell itself. And that's the position Arbor Pharmaceuticals is reportedly in right now.

Ascension hospitals bar Genentech reps after cancer drug distribution switch

One hospital chain has struck back at Roche's Genentech unit for switching its top 3 cancer treatments to specialty distributors. Ascension Health, a Roman Catholic-based group of more than 130 hospitals, is barring Genentech sales reps at the door.

Salix drops Cosmo buy, opting to talk takeover with Actavis

Chalk up a victory for the U.S. Treasury Department, whose new rules put the kibosh on Salix Pharmaceuticals' tax inversion deal for Cosmo's Irish unit. Instead, the North Carolina company is reportedly in talks to sell itself--but to Actavis, not Allergan.

NICE nixes Roche's new leukemia drug Gazyvaro despite discount offer

Roche just can't win with the U.K.'s drug price watchdog, the National Institute for Health and Care Excellence (NICE). In August, the agency decided the company's heralded breast cancer drug Kadcyla was too expensive for the country's health system to cover. Now NICE has slapped Roche with a preliminary thumbs-down on Gazyvaro, its new drug to treat chronic lymphocytic leukemia (CLL).

Merck's Gardasil successor could block 90% of cervical cancers--but first, uptake has to improve

According to new research, Merck's investigational, 9-valent HPV vaccine has the potential to block about 90% of invasive cervical cancer cases worldwide. But realizing that potential will be no piece of cake.

New wave of HER2 meds to fuel huge leap in breast cancer market

HER2-positive breast cancer treatments already do pretty well for themselves, with Roche's Herceptin taking the No. 8 spot last year on the world's list of best-selling drugs. But according to a new report, their sales are about to jump--big time.

Forest, Otsuka and J&J spend the most on fees and food for doctors

The Sunshine Act data's been out in the open for a couple of days now (well--most of it), and despite the database's clunkiness, the number crunching is well underway. The Wall Street Journal, for one, has broken down which pharma companies topped the doc-paying list in a variety of different spending categories.

Genentech tightens distribution on top cancer meds, triggering blowback from hospitals

Roche's Genentech unit is getting some high-profile blowback from a change to its distribution model on three top cancer meds. Hospital and pharmacy executives claim the new regime--which restricts Avastin, Rituxan and Herceptin to a half-dozen specialty distributors--will cost them big money.

What's #trending in pharma on social media? Investors are listening to find out

Pharma's social media evangelists have been urging companies to lend an ear to the chatter on Twitter, Facebook, patient forums, physician networking sites and the like. It's a way to engage with patients, monitor doctors' opinions, tailor marketing and spot safety concerns, they say.

Zogenix races to FDA with abuse-deterrent version of maligned pain pill Zohydro

Ever since the FDA approved Zogenix's all-hydrocodone painkiller Zohydro last year, both the agency and the company have faced a storm of criticism. The powerful pill, without tamper-resistant features, was destined to be abused, they claimed.

Top 10 pharma companies by employees - 2014

It is probably no surprise that the 10 largest Big Pharma companies came into 2014 with far fewer employees than they had the previous year. After all, revenues have been off at those companies as...

FDA flags particle problems in latest Hospira warning letter

Hospira's FDA woes have moved to Australia. The agency scolded the U.S.-based company in a warning letter based on an injectables plant inspection in late February and early March, according to a Wednesday securities filing.

Sunshine fact: $3.5B + 546,000 docs equals one unwieldy database

A few things are certain about the Sunshine Act data that hit the Internet Tuesday afternoon. One, it's incomplete. Two, it's controversial. Three, the numbers are pretty staggering, with $3.5 billion in payments to 546,000 doctors and 1,360 research institutions over a 5-month period.